DnB Asset Management AS Takes $455,000 Position in Cryoport, Inc. (NASDAQ:CYRX)

DnB Asset Management AS purchased a new stake in shares of Cryoport, Inc. (NASDAQ:CYRXGet Rating) during the 2nd quarter, Holdings Channel reports. The fund purchased 14,700 shares of the consumer goods maker’s stock, valued at approximately $455,000.

Several other large investors have also made changes to their positions in CYRX. Vanguard Group Inc. lifted its stake in Cryoport by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,515,305 shares of the consumer goods maker’s stock valued at $122,720,000 after buying an additional 159,133 shares during the period. Invesco Ltd. lifted its stake in Cryoport by 17.7% in the first quarter. Invesco Ltd. now owns 3,228,313 shares of the consumer goods maker’s stock valued at $112,700,000 after buying an additional 485,972 shares during the period. BlackRock Inc. lifted its stake in Cryoport by 2.0% in the first quarter. BlackRock Inc. now owns 3,028,269 shares of the consumer goods maker’s stock valued at $105,718,000 after buying an additional 59,877 shares during the period. Victory Capital Management Inc. lifted its stake in Cryoport by 29.1% in the first quarter. Victory Capital Management Inc. now owns 1,661,069 shares of the consumer goods maker’s stock valued at $57,632,000 after buying an additional 374,045 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in Cryoport by 21.9% in the first quarter. Clearbridge Investments LLC now owns 1,207,444 shares of the consumer goods maker’s stock valued at $42,152,000 after buying an additional 216,590 shares during the period. Institutional investors and hedge funds own 90.33% of the company’s stock.

Insider Buying and Selling

In related news, Director Robert J. Hariri sold 2,000 shares of the stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $43.29, for a total transaction of $86,580.00. Following the completion of the transaction, the director now directly owns 7,911 shares in the company, valued at $342,467.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Robert J. Hariri sold 2,000 shares of the stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $43.29, for a total transaction of $86,580.00. Following the completion of the transaction, the director now directly owns 7,911 shares in the company, valued at $342,467.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard J. Berman sold 2,708 shares of the stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $43.05, for a total value of $116,579.40. Following the transaction, the director now owns 107,203 shares of the company’s stock, valued at $4,615,089.15. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Cryoport Stock Down 3.0 %

Shares of Cryoport stock opened at $27.20 on Friday. Cryoport, Inc. has a 1 year low of $19.82 and a 1 year high of $86.30. The business has a 50-day moving average of $35.66 and a two-hundred day moving average of $31.00. The company has a market capitalization of $1.32 billion, a P/E ratio of -4.40 and a beta of 1.17. The company has a debt-to-equity ratio of 0.73, a current ratio of 14.21 and a quick ratio of 13.69.

Cryoport (NASDAQ:CYRXGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The consumer goods maker reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). The business had revenue of $64.20 million during the quarter, compared to the consensus estimate of $64.58 million. Cryoport had a negative return on equity of 14.43% and a negative net margin of 125.96%. The firm’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.16) earnings per share. As a group, equities analysts predict that Cryoport, Inc. will post -0.78 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC increased their target price on Cryoport from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, July 12th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cryoport has a consensus rating of “Buy” and an average price target of $61.33.

About Cryoport

(Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

See Also

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc. (NASDAQ:CYRXGet Rating).

Institutional Ownership by Quarter for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.